Last reviewed · How we verify
NVC-422
At a glance
| Generic name | NVC-422 |
|---|---|
| Also known as | Sodium salt of 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate |
| Sponsor | NovaBay Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis (PHASE2)
- Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis (PHASE2)
- Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation (PHASE2)
- Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients (PHASE2)
- Safety and Efficacy of Topical NVC-422 Gel in Impetigo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |